<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-type="olc" bill-stage="Introduced-in-Senate" dms-id="A1" public-private="public" slc-id="S1-KEL25087-K4J-VP-L2X"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>115 S475 IS: Alternatives to Prevent Addiction In the Nation Act</dc:title>
<dc:publisher>U.S. Senate</dc:publisher>
<dc:date>2025-02-06</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">II</distribution-code><congress>119th CONGRESS</congress><session>1st Session</session><legis-num>S. 475</legis-num><current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber><action><action-date date="20250206" legis-day="20250205">February 6 (legislative day, February 5), 2025</action-date><action-desc><sponsor name-id="S384">Mr. Tillis</sponsor> (for himself, <cosponsor name-id="S406">Mr. Kelly</cosponsor>, <cosponsor name-id="S372">Mrs. Capito</cosponsor>, <cosponsor name-id="S362">Mr. Kaine</cosponsor>, <cosponsor name-id="S416">Mrs. Britt</cosponsor>, <cosponsor name-id="S324">Mrs. Shaheen</cosponsor>, <cosponsor name-id="S417">Mr. Budd</cosponsor>, <cosponsor name-id="S337">Mr. Coons</cosponsor>, <cosponsor name-id="S287">Mr. Cornyn</cosponsor>, <cosponsor name-id="S370">Mr. Booker</cosponsor>, <cosponsor name-id="S347">Mr. Moran</cosponsor>, <cosponsor name-id="S330">Mr. Bennet</cosponsor>, <cosponsor name-id="S429">Mr. Banks</cosponsor>, <cosponsor name-id="S413">Mr. Padilla</cosponsor>, <cosponsor name-id="S375">Mr. Daines</cosponsor>, <cosponsor name-id="S327">Mr. Warner</cosponsor>, and <cosponsor name-id="S395">Mrs. Hyde-Smith</cosponsor>) introduced the following bill; which was read twice and referred to the <committee-name committee-id="SSFI00">Committee on Finance</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title>To amend title XVIII of the Social Security Act to ensure appropriate access to non-opioid pain management drugs under part D of the Medicare program.</official-title></form><legis-body style="OLC" display-enacting-clause="yes-display-enacting-clause" id="H97286D20F8634E6C8E95B30B06F7E348"><section section-type="section-one" id="H4CE1C0F4C5524720B2C462961D9D54D4"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Alternatives to Prevent Addiction In the Nation Act</short-title></quote> or the <quote><short-title>Alternatives to PAIN Act</short-title></quote>.</text></section><section id="H51C765457B134BFB9633179481F433D0"><enum>2.</enum><header>Appropriate cost-sharing for qualifying non-opioid pain management drugs under Medicare part D</header><subsection id="H7882DD2859084FE3B43270B79EA7D3C1"><enum>(a)</enum><header>Medicare part D</header><text>Section 1860D–2 of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395w-102">42 U.S.C. 1395w–102</external-xref>) is amended—</text><paragraph id="H079F0B98BC7248D782804F27EEEAB138"><enum>(1)</enum><text>in subsection (b)—</text><subparagraph id="HE1F5DD51935B4094BAEC52D2DA92C15D"><enum>(A)</enum><text>in paragraph (1)(A), in the matter preceding clause (i), by striking <quote>paragraphs (8) and (9)</quote> and inserting <quote>paragraphs (8), (9), and (10)</quote>;</text></subparagraph><subparagraph id="H7F60B9695D734CF7BACE9268BBC68AFD"><enum>(B)</enum><text>in paragraph (2)(A), in the matter preceding clause (i), by striking <quote>paragraphs (8) and (9)</quote> and inserting <quote>paragraphs (8), (9), and (10)</quote>; and</text></subparagraph><subparagraph id="H30C4F26C1CE9410E981250380E24C533"><enum>(C)</enum><text>by adding at the end the following new paragraph:</text><quoted-block style="OLC" id="HB97F147A740143778A9F0D0F1B2FCD5E"><paragraph id="HFB6737CDEB104BC78B4EAC038CD3EFC6"><enum>(10)</enum><header>Treatment of cost-sharing for qualifying non-opioid pain management drugs</header><subparagraph id="HB90070AB8BA844029E2F47A9067EA678"><enum>(A)</enum><header>In general</header><text>For plan years beginning on or after January 1, 2026, with respect to a covered part D drug that is a qualifying non-opioid pain management drug (as defined in subparagraph (B))—</text><clause id="H7768E7D7ACA6453C95D27674DE449B88"><enum>(i)</enum><text>the deductible under paragraph (1) shall not apply; and</text></clause><clause id="HAB8F6BC85FE041EAAFB277F5EAF84955"><enum>(ii)</enum><text>such drug shall be placed on the lowest cost-sharing tier, if any, for purposes of determining the maximum co-insurance or other cost-sharing for such drug.</text></clause></subparagraph><subparagraph id="HE0507B4FADC94FCFBE894EF392625859"><enum>(B)</enum><header>Qualifying non-opioid pain management drugs</header><text>In this paragraph, the term <quote>qualifying non-opioid pain management drug</quote> means a drug or biological product—</text><clause id="HB278F0FB3D734B0591DAC4EC1E6EA034"><enum>(i)</enum><text>that has a label indication approved by the Food and Drug Administration to reduce postoperative pain or any other form of acute pain;</text></clause><clause id="H275924F8B74E4254BBBC2BE868C61C08"><enum>(ii)</enum><text>that does not act upon the body’s opioid receptors;</text></clause><clause id="H97834FC6230B491491622AD45E4106CB"><enum>(iii)</enum><text>for which there is no other drug or product that is—</text><subclause id="H218F677D172346DE8BB14907D140EFE5"><enum>(I)</enum><text>rated as therapeutically equivalent (under the Food and Drug Administration’s most recent publication of <quote>Approved Drug Products with Therapeutic Equivalence Evaluations</quote>); and</text></subclause><subclause id="HF3BD4AB44BD5430ABBDBCC51A2CF8B4C"><enum>(II)</enum><text>sold or marketed in the United States; and</text></subclause></clause><clause id="HA7916E67B05344E6BDAD667854302DD1"><enum>(iv)</enum><text>for which the wholesale acquisition cost (as defined in section 1847A(c)(6)(B)), for a monthly supply does not exceed the monthly specialty-tier cost threshold as determined by the Secretary from time to time.</text></clause></subparagraph></paragraph><after-quoted-block>; and</after-quoted-block></quoted-block></subparagraph></paragraph><paragraph id="H16988BD26811421FA3D02942041E8E09"><enum>(2)</enum><text>in subsection (c), by adding at the end the following new paragraph:</text><quoted-block style="OLC" id="HE535863E63344AC9AFE4BAAD948E08BA"><paragraph id="H5EBF49CCD5C14BC7B31988432F4BB7D4"><enum>(7)</enum><header>Treatment of cost-sharing for qualifying non-opioid pain management drugs</header><text>The coverage is provided in accordance with subsection (b)(10).</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection id="H86A2A55CCCA94D8E8C423CDA2B6832CC"><enum>(b)</enum><header>Conforming amendments to cost-Sharing for low-Income individuals</header><text>Section 1860D–14(a) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395w-114">42 U.S.C. 1395w–114(a)</external-xref>) is amended—</text><paragraph id="HB62844632E854DCCB3E15C4D948ADE45"><enum>(1)</enum><text>in paragraph (1)(D), in each of the clauses (ii) and (iii), by striking <quote>Subject to paragraph (6)</quote> and inserting <quote>Subject to paragraphs (6) and (7)</quote>; and</text></paragraph><paragraph id="HFFE2362353FA4C88824E6332B4AFA1CA"><enum>(2)</enum><text>by adding at the end the following new paragraph:</text><quoted-block style="OLC" id="H139B735CDB47476C8BEC8AA59589941A"><paragraph id="HD9604C0CBB8C4A0D8ED1187E03C7FF4F"><enum>(7)</enum><header>Treatment of cost-sharing or deductible for qualifying non-opioid pain management drugs</header><text>For plan years beginning on or after January 1, 2026, with respect to a covered part D drug that is a qualifying non-opioid pain management drug (as defined in section 1860D–2(b)(10)(B))—</text><subparagraph id="H029A919A09B746E3AFB9C2F5899FCE02"><enum>(A)</enum><text>the deductible under section 1860D–2(b)(1) shall not apply; and</text></subparagraph><subparagraph id="H4091151791BD4C49BE15855D79F6560A"><enum>(B)</enum><text>such drug shall be placed on the lowest cost-sharing tier, if any, for purposes of determining the maximum co-insurance or other cost-sharing for such drug.</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection></section><section id="HFD8EC2D08EC64693A3EFC81E94738572"><enum>3.</enum><header>Prohibition on the use of step therapy and prior authorization for qualifying non-opioid pain management drugs under medicare part D</header><text display-inline="no-display-inline">Section 1860D–4(c) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395w-104">42 U.S.C. 1395w–104</external-xref>) is amended—</text><paragraph commented="no" display-inline="no-display-inline" id="id2d3ffe3e2c78448a850b235beffb68a6"><enum>(1)</enum><text>by redesignating paragraph (6), as added by section 50354 of division E of the Bipartisan Budget Act of 2018 (<external-xref legal-doc="public-law" parsable-cite="pl/115/123">Public Law 115–123</external-xref>), as paragraph (7); and</text></paragraph><paragraph commented="no" display-inline="no-display-inline" id="id0c51479a9bb24ff0af9419d8d86e4f44"><enum>(2)</enum><text display-inline="yes-display-inline">by adding at the end the following paragraph:</text><quoted-block style="OLC" id="HB568D062747B434AB8C583EBA8088566"><paragraph id="H03E7A8BBB4F1425C83B9D3B3E97BC8EC"><enum>(8)</enum><header>Prohibition on use of step therapy and prior authorization for qualifying non-opioid pain management drugs</header><subparagraph id="H0F948F2E9C87494CB15415D80F574D0B"><enum>(A)</enum><header>In general</header><text>For plan years beginning on or after January 1, 2026, a prescription drug plan or an MA–PD plan may not, with respect to a qualifying non-opioid pain management drug (as defined in section 1860D–2(b)(10)(B)) for which coverage is provided under such plan, impose any—</text><clause id="H7394A6EA6BA644E0BA0A31BCE29A1CFF"><enum>(i)</enum><text>step therapy requirement under which an individual enrolled under such plan is required to use an opioid prior to receiving such drug; or</text></clause><clause id="HD7C6018E3C1C49139DF330F5F201AB8C"><enum>(ii)</enum><text>prior authorization requirement.</text></clause></subparagraph><subparagraph id="H7DA62C8ED6FE4F0FA1940A988C2DE97C"><enum>(B)</enum><header>Step therapy</header><text>In this paragraph, the term <quote>step therapy</quote> means a drug therapy utilization management protocol or program that requires use of an alternative, preferred prescription drug or drugs before the plan approves coverage for the non-preferred drug therapy prescribed.</text></subparagraph><subparagraph id="H2364E6304F044E649A662BD515F8DBD5"><enum>(C)</enum><header>Prior authorization</header><text>In this paragraph, the term <quote>prior authorization</quote> means any requirement to obtain approval from a plan prior to the furnishing of a drug.</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></section></legis-body></bill> 

